

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449-001 GRADE 6-8

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3	Attorney Docket Number	51283-00002
-------	---	----	---	------------------------	-------------

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
JK	AA	US -4,127,481	11/28/1978	Malchesky et al.	
	AB	US -4,231,871	11/04/1980	Lipps et al.	
	AC	US -4,267,047	05/12/1981	Henne et al.	
	AD	US -4,269,708	05/26/1981	Bonomini et al.	
	AE	US -4,617,115	10/14/1986	Vantard	
	AF	US -4,747,822	05/31/1988	Peabody	
	AG	US -4,769,037	09/06/1988	Midcalf	
	AH	US -5,015,388	05/14/1991	Pusineri et al.	
	AI	US -5,571,418	11/05/1996	Lee et al.	
	AJ	US -6,008,049	12/28/1999	Naughton et al.	
	AK	US -6,186,146	02/13/2001	Glickman	
	AL	US -6,287,516	09/11/2001	Matson et al.	
	AM	US -6,372,482	04/16/2002	Mitrani	
JK	AN	US -2001/0051106	12/13/2001	Matson et al.	

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>J Kim</i>	Date Considered	2/28/06
-----------------------	--------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.4. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	3	Application Number	10/785,215
-------	---	----	---	--------------------	------------

Filing Date	02/23/2004
First Named Inventor	Craig P. Roberts
Group Art Unit	4614 1723
Examiner Name	Unassigned KIM
Attorney Docket Number	51283-00002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JK	AR	Anand A.C., Nightingale P., Neuberger J.M., Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria, J Hepatology, 1997; 26:62-68.	
	AS	Ash S.R., Treatment of Acute Hepatic Failure with Encephalopathy: A review, Int. J. Artif Organs, 1991; 14:191-195.	
	AT	Awad S.S. et al., A novel stable reproducible model of hepatic failure canines, J. Surg. Res., 2000; 94:167-71.	
	AU	Bende S. et al., Elimination of endotoxin from the blood by extracorporeal activated charcoal hemoperfusion in experimental canine endotoxin shock, Circulatory Shock, 1986; 19:239-244.	
	AV	Ellis A.J. et al., Temporary extracorporeal liver support for several acute alcoholic hepatitis using the BioLogic-DT., Int. J. Artif. Organs, 1999; 22:27-34.	
	AW	Falhenhagen D. et al., Fractionated plasma separation and adsorption system: A novel system for blood purification to remove albumin bound substances, Artif. Organs, 1999; 23:81-6.	
	AX	Hughes R.D. and Williams R., Use of sorbent columns and haemofiltration in fulminant hepatic failure, Blood Purif., 1993; 11:163-9.	
	AY	Hughes R.D. et al., Artificial liver support in acute liver failure: a review of studies at King's, Artif. Organs 1992; 16:167-70.	
	AZ	Hughes R.D., In-vitro blood compatibility studies on a new polymer-coated charcoal for haemoperfusion, The Inter'l Journal of Artificial Organs, 1980; 3(5): 277-279.	
	BA	Hughes R.D., Platelet function during haemoperfusion in acute liver failure, The Inter'l Journal of Artificial Organs, 1980; 3(1):30-34.	
	BB	Kellum J.A. and Dishart M. K., Effect of Hemofiltration Filter Adsorption on Circulating IL-6 Levels in Spectic Rats, Critical Care 2002, 6:429-433.	
	BC	Makin A.J. et al., System and hepatic hemodynamic changes in acute liver injury. Am. J. Physiol., 1997; 272:G617-G625.	
	BD	Morimoto T. et al., Plasma absorption using bilirubin-absorbent materials as a treatment for patients with hepatic failure, Artificial Organs 1989, 447-452.	
	BE	Mullen KD, Dasarathy S., Hepatic encephalopathy. ER Schiff et al. (eds), Schiff's Diseases of the Liver, 8 th edition, Lippincott-Raven Publishers, Philadelphia, 1999	
	BF	Nagaki M. et al., In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines, Circulatory Shock 1992; 38:182-8.	
	BG	Nagaki M. et al., Removal of endotoxin and cytokines by absorbent and the effect of plasma protein binding, Liver Unit, King's College School of Medicine and Dentistry 1991; 4:43-50.	
JK	BH	Nakae H, Yonekawa C, Wada H, Asanuma Y, Sato T, Tanaka H. Effectiveness of combining plasma exchange and continuous hemodiafiltration (combined modality therapy in a parallel circuit) in the treatment of patients with acute hepatic failure, Ther Apher., 2001;5:471-475.	

Examiner Signature	JKim	Date Considered	2/28/06
-----------------------	------	--------------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.4. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	3	of	3	Application Number	10/785,215
				Filing Date	02/23/2004
				First Named Inventor	Craig P. Roberts
				Group Art Unit	4614 1723
				Examiner Name	Unassigned KIM
				Attorney Docket Number	51283-00002

NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JK	BI	Odnopozov V.A. et al. Effect of hemocarboperfusion on organ blood flow and survival in procine endotoxic shock. Crit. Care Med., 1996; 24:2020-2026.	
	BJ	Peltekian KM, Levy GA : Role of cytokines and immune mechanisms in acute liver failure. In Acute Liver Failure. Edited by Lee WM et al. (eds.), Cambridge Press; 1997, pages 67-78.	
	BK	Rahman T.M. and Hodgson H.J.. Review article: Liver Support Systems in Acute Hepatic Failure. Aliment. Pharmacol. Ther., 1999; 13: 1255-1272.	
	BL	Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, La Greca G, Inguaggiato P, Maggiore U, De Nitti C, Wratten ML, Ricci Z, Tetta C., A pilot study of coupled plasma filtration with adsorption in septic shock, Crit Care Med 2002;30:1250-55.	
	BM	Ryan C.J. et al., Preclinical evaluation of haemosorbents, The Inter'l Journal of Artificial Organs 1986; 9-5:293-296.	
	BN	Ryan C.J. et al., Repeated membrane plasma separation with on-line sorbent treatment of plasma in the conscious rat, 1986; Artificial Organs, 10(2):135-144.	
	BO	Schiødt FV, Atillasoy E, Shakil AO, et al., Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg., 1999; 5:29-34.	
	BP	Schiødt FV, Rochling FA, Casey DL, Lee WM, Acetaminophen toxicity in an urban county hospital. N Engl J Med., 1997; 337:1112-1117.	
	BQ	Strange J. et al., Liver support by extracorporeal blood purification-A clinical observation, German Ministry for Research and Technology, Germany, 2000; 6(5):603-613.	
	BR	Sudan DL, Shaw BW Jr, Fox IJ, Lagnas AN, Long-term follow up of auxiliary orthotopic liver transplantation for the treatment of fulminant hepatic failure. Surgery, 1997; 122(4):777-778.	
	BS	Sussman N.L., Chong M.G., Koussayer T. et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology, 1992; 16: 60-65.	
	BT	Terblanche J. and Hickman R., Animal models of fulminant liver failure, Digest. Dis. Sci. 1991; 36:770-4.	
	BU	Tetta C. et al., Endotoxin and cytokine removal in sepsis, Ther. Apher 2002, 16:109-115	
	BV	Wedon J.A., Harrison P.M., Keays R., Williams R., Cerebral blood flow and metabolism in fulminant liver failure, Hepatology, 1994; 19: 1407-141319.	
	BW	Wehler M. et al., Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems, Hepatology, 2001; 34:255-261.	
JK	BX	Williams R., New directions in acute liver failure, J Royal College of Physicians of London, 1994; 28:552-559.	

Examiner Signature	<i>JK Kim</i>	Date Considered	2/28/06
--------------------	---------------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.4. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449A/PTO

PTO/SB/08A (07-05)

Approved for use through 07/31/2006.OMB 0651-00311

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

(use as many sheets as necessary)

Sheet1

of

1

Attorney Docket Number

51283-00002

[illegible]

**Examiner
Signature**

JKwin

Date _____

Considered


2/28/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.4. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.** SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199(1-800-786-9199) and select option 2.

K:\51283\00002 - PLASMA DETOXIFICATION SYSTEM AND METHOD\00002US\SUPPLEMENTAL IDS FORM (9-30-06).DOC



PTO/SB/08A (07-05)

Approved for use through 07/31/2006.OMB 0651-00311

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 449A/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/785,215
Filing Date	02/23/2004
First Named Inventor	Craig P. Roberts et al.
Group Art Unit	1814 1723
Examiner Name	KIM
Attorney Docket Number	51283-00002

Sheet

1

of

1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
JK		US 5,091,091 5,091,091	02/25/1992	Terman et al.	
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		County Code ³ Number ⁴ Kind Code ⁵ (if known)				
JK		EP 0787500	08/06/1997	Belco SPA		
JK		DE 3110128 A1	09/23/1982	Fraunhofer- Gesellschaft		

Examiner Signature	<i>JKim</i>	Date Considered	2/28/06
-----------------------	-------------	--------------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.4. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199(1-800-786-9199) and select option 2.

K:5128300002 - PLASMA DETOXIFICATION SYSTEM AND METHOD/00002US/DS FORM (11-18-05).DOC